{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:40:02Z","timestamp":1792518002809,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023280","name":"Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128504","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T20:15:56Z","timestamp":1774556156000},"page":"128504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study"],"prefix":"10.1016","volume":"80","author":[{"given":"Airi","family":"P\u00f5der","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzi","family":"Trinidad-Aseron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Van Twuijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Versage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hohenboken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128504_bb0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41586-024-08054-z","article-title":"The global H5N1 influenza panzootic in mammals","volume":"637","author":"Peacock","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128504_bb0010","unstructured":"Centers for Disease Control and Prevention. Influenza historic timeline 1930 and beyond, https:\/\/archive.cdc.gov\/www_cdc_gov\/flu\/pandemic-resources\/pandemic-timeline-1930-and-beyond.htm; 2019 [Accessed 10 July 2025]."},{"key":"10.1016\/j.vaccine.2026.128504_bb0015","first-page":"1","article-title":"Updated preparedness and response framework for influenza pandemics","volume":"63","author":"Holloway","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128504_bb0020","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1056\/NEJMp0903906","article-title":"The signature features of influenza pandemics\u2014implications for policy","volume":"360","author":"Miller","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128504_bb0025","unstructured":"World Health Organization. Avian Influenza Weekly Update Number 1003, https:\/\/cdn.who.int\/media\/docs\/default-source\/wpro---documents\/emergency\/surveillance\/avian-influenza\/ai_20250117.pdf. 2025 [Accessed 9 July 2025]."},{"key":"10.1016\/j.vaccine.2026.128504_bb0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJMc2415890","article-title":"Critical illness in an adolescent with influenza a(H5N1) virus infection","volume":"392","author":"Jassem","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128504_bb0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/vaccines10040589","article-title":"Global pandemic preparedness: optimizing our capabilities and the influenza experience","volume":"10","author":"Rockman","year":"2022","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128504_bb0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/vaccines8020211","article-title":"Pandemic influenza vaccines: what did we learn from the 2009 pandemic and are we better prepared now?","volume":"8","author":"Rockman","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128504_bb0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","article-title":"Global production capacity of seasonal and pandemic influenza vaccines in 2019","volume":"39","author":"Sparrow","year":"2021","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128504_bb0050","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/vaccines10050819","article-title":"An overview of vaccine adjuvants: current evidence and future perspectives","volume":"10","author":"Facciol\u00e0","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128504_bb0055","unstructured":"Centers for Disease Control and Prevention. Adjuvants and vaccines, https:\/\/www.cdc.gov\/vaccine-safety\/about\/adjuvants.html. 2024 [Accessed 10 July 2025]."},{"key":"10.1016\/j.vaccine.2026.128504_bb0060","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128504_bb0065","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza a\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128504_bb0070","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128504_bb0075","first-page":"323","article-title":"Adjuvants for pandemic influenza vaccines","volume":"333","author":"Atmar","year":"2009","journal-title":"Curr Top Microbiol Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.128504_bb0080","article-title":"Recent advances in influenza vaccines","volume":"305","author":"Pawelec","year":"2020","journal-title":"F1000Res"},{"key":"10.1016\/j.vaccine.2026.128504_bb0085","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz107","article-title":"Safety and immunogenicity of MF59-adjuvanted cell culture-derived a\/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly","volume":"6","author":"Frey","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128504_bb0090","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/INF.0000000000002345","article-title":"Safety, tolerability and immunogenicity of an MF59-adjuvanted, cell culture-derived, a\/H5N1, subunit influenza virus vaccine: results from a dose-finding clinical trial in healthy pediatric subjects","volume":"38","author":"Chanthavanich","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128504_bb0095","doi-asserted-by":"crossref","unstructured":"Jelinek T, Schwarz TF, Reisinger E, Malfertheiner P, Versage E, Van Twuijver E, et al. Safety, tolerability, and immunogenicity of aH5N1 vaccine in adults with and without underlying medical conditions. Vaccines (Basel) 2024;12(5):481. doi:https:\/\/doi.org\/10.3390\/vaccines12050481.","DOI":"10.3390\/vaccines12050481"},{"key":"10.1016\/j.vaccine.2026.128504_bb0100","doi-asserted-by":"crossref","first-page":"e762","DOI":"10.1542\/peds.2009-2628","article-title":"Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence","volume":"126","author":"Vesikari","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128504_bb0105","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1097\/INF.0000000000003247","article-title":"Immunogenicity and safety of AS03-adjuvanted H5N1 influenza vaccine in children 6-35 months of age: results from a phase 2, randomized, observer-blind, multicenter, dose-ranging study","volume":"40","author":"Kim","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128504_bb0110","doi-asserted-by":"crossref","unstructured":"Verschoor CP, Singh P, Russell ML, Bowdish DM, Brewer A, Cyr L, et al. Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children. PLoS One 2015;10:e0131531. doi:https:\/\/doi.org\/10.1371\/journal.pone.0131531.","DOI":"10.1371\/journal.pone.0131531"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:28Z","timestamp":1792515748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"alternative-id":["S0264410X26003129"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128504","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128504"}}